Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 408Rectal Neoplasms 152Colonic Neoplasms 150Pancreatic Neoplasms 114Stomach Neoplasms 110Neoplasm Metastasis 88Neoplasms 74Esophageal Neoplasms 60Small Cell Lung Carcinoma 45Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 38Esophageal Squamous Cell Carcinoma 33Brain Neoplasms 33Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Recurrence 14Cholangiocarcinoma 14

Interventions

anlotinib 1S 1 (combination) 1Oxaliplatin 1Irinotecan 1Immune Checkpoint Inhibitors 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Overall Survival × Irinotecan × Clear all
NCT03726021 2023-03-29

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Completed
47 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡